comscoreImmunotherapy for Breast Cancer: Part 1

Immunotherapy for Breast Cancer: Part 1

Sherene Loi, MD, PhD discusses the PANACEA trial, which looked at using the immunotherapy medicine Keytruda in breast cancer patients.
Apr 6, 2018

Much of Dr. Sherene Loi's clinical research focuses on investigating new treatments, such as immunotherapy, especially for breast cancers that have become resistant to standard treatments.

Listen to the podcast to hear Dr. Loi explain:

  • results from the PANACEA trial, which looked at using the immunotherapy medicine Keytruda (chemical name: pembrolizumab) along with Herceptin to treat Herceptin-resistant, HER2-positive, advanced-stage breast cancer that had high levels of PDL-1, a biomarker that indicates that Keytruda will be effective

  • how an immunotherapy medicine like Keytruda works

  • what tumor-infiltrating lymphocytes (TILs) are and why cancer tumors with high numbers of TILs seem to respond better to immunotherapy

  • side effects of immunotherapy medicines

About the guest
Sherene Loi headshot
Sherene Loi, MD, PhD

Dr. Sherene Loi is a medical oncologist who specializes in treating breast cancer. In addition to treating patients, particularly patients diagnosed with HER2-positive breast cancer, she also leads the Translation Breast Cancer Genomics and Therapeutics Laboratory at the Peter MacCallum Cancer Centre in Melbourne, Australia, where she is a professor.

— Last updated on May 3, 2022, 2:05 PM

Support to produce more content like this

Your donation goes directly to what you read, hear, and see on